These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 28481884)

  • 1. New advances in DPYD genotype and risk of severe toxicity under capecitabine.
    Etienne-Grimaldi MC; Boyer JC; Beroud C; Mbatchi L; van Kuilenburg A; Bobin-Dubigeon C; Thomas F; Chatelut E; Merlin JL; Pinguet F; Ferrand C; Meijer J; Evrard A; Llorca L; Romieu G; Follana P; Bachelot T; Chaigneau L; Pivot X; Dieras V; Largillier R; Mousseau M; Goncalves A; Roché H; Bonneterre J; Servent V; Dohollou N; Château Y; Chamorey E; Desvignes JP; Salgado D; Ferrero JM; Milano G
    PLoS One; 2017; 12(5):e0175998. PubMed ID: 28481884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highlight on DPYD gene polymorphisms and treatment by capecitabine (.).
    Milano G
    Scand J Clin Lab Invest Suppl; 2016; 245():S30-3. PubMed ID: 27454530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
    Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
    Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
    García-González X; Kaczmarczyk B; Abarca-Zabalía J; Thomas F; García-Alfonso P; Robles L; Pachón V; Vaz Á; Salvador-Martín S; Sanjurjo-Sáez M; López-Fernández LA
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):45-54. PubMed ID: 32529295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
    Stavraka C; Pouptsis A; Okonta L; DeSouza K; Charlton P; Kapiris M; Marinaki A; Karapanagiotou E; Papadatos-Pastos D; Mansi J
    Breast Cancer Res Treat; 2019 Jun; 175(2):511-517. PubMed ID: 30746637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
    Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
    Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
    Meulendijks D; Henricks LM; Sonke GS; Deenen MJ; Froehlich TK; Amstutz U; Largiadèr CR; Jennings BA; Marinaki AM; Sanderson JD; Kleibl Z; Kleiblova P; Schwab M; Zanger UM; Palles C; Tomlinson I; Gross E; van Kuilenburg AB; Punt CJ; Koopman M; Beijnen JH; Cats A; Schellens JH
    Lancet Oncol; 2015 Dec; 16(16):1639-50. PubMed ID: 26603945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
    Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
    Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
    Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
    Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
    van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study.
    De Metz C; Hennart B; Aymes E; Cren PY; Martignène N; Penel N; Barthoulot M; Carnot A
    Cancer Med; 2024 Mar; 13(6):e7066. PubMed ID: 38523525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
    Saif MW
    Cancer Genomics Proteomics; 2013; 10(2):89-92. PubMed ID: 23603345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
    Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM
    Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
    Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
    Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.
    Paulsen NH; Pfeiffer P; Ewertz M; Fruekilde PBN; Feddersen S; Holm HS; Bergmann TK; Qvortrup C; Damkier P
    ESMO Open; 2023 Feb; 8(1):100782. PubMed ID: 36791638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a
    Ockeloen CW; Raaijmakers A; Hijmans-van der Vegt M; Bierau J; de Vos-Geelen J; Willemsen AE; van den Bosch BJ; Coenen MJ
    J Oncol Pharm Pract; 2023 Jan; 29(1):5-13. PubMed ID: 34797200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies.
    Galarza AF; Linden R; Antunes MV; Hahn RZ; Raymundo S; da Silva AC; Staggemeier R; Spilki FR; Schwartsmann G
    Clin Biochem; 2016 Nov; 49(16-17):1221-1226. PubMed ID: 27399164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study.
    Kleinjan JP; Brinkman I; Bakema R; van Zanden JJ; van Rooijen JM
    Anticancer Drugs; 2019 Apr; 30(4):410-415. PubMed ID: 30628914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.